secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001628280-25-022167
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates
--------------------------------------------------------------------------------

- Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.
- Reiterated FY 2025 revenue guidance $900-950M; cash/investments $570.8M (down from $603.2M due to buybacks).
- Relacorilant NDA for Cushing's under FDA review with PDUFA Dec 30, 2025; NDA for ovarian cancer expected Q3 2025.
- Phase 3 ROSELLA trial met PFS and OS endpoints; results to be presented at ASCO June 2025.
- Dazucorilant ALS trial missed primary endpoint; exploratory survival benefit at 1yr (HR 0.16, p=0.0009); seeking regulatory input.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/0001628280-25-022167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828025022167/cort-20250505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-022167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer